# Trump Sets Generic-Drug Tariffs Rising to 100 Percent in 2028 and 200 Percent a Year Later

A two-year exemption starting in August precedes steep tariffs designed to move production into the United States, with India, which supplies roughly half of American generics, the most exposed.

- Published: 2026-07-22T05:31:48.407Z
- Canonical: https://polylog.news/2026-07-22/trump-sets-generic-drug-tariffs-rising-to-100-percent-in-202
- Publisher: Polylog (Global desk)
- Section: macro
- Sources: [Globes](https://www.globes.co.il/news/article.aspx?did=1001550093#utm_source=RSS), [CNBC](https://www.cnbc.com/2026/07/22/trump-generic-drugs-tariffs-medicine-trade-.html), [Bloomberg](https://www.bloomberg.com/news/articles/2026-07-21/trump-plans-100-tariff-on-generic-drugs-from-august-2028)

President Donald Trump announced a phased tariff on imported generic pharmaceuticals, structured to give manufacturers time to build American plants before the penalties take effect. The Israeli financial daily Globes [reported](https://www.globes.co.il/news/article.aspx?did=1001550093#utm_source=RSS) that generic imports will be exempt from duty for two years, after which tariffs of 100 percent and then 200 percent apply.

The mechanics, as [described by CNBC](https://www.cnbc.com/2026/07/22/trump-generic-drugs-tariffs-medicine-trade-.html) and [Bloomberg](https://www.bloomberg.com/news/articles/2026-07-21/trump-plans-100-tariff-on-generic-drugs-from-august-2028), set the rate at zero for two years from August 1, then 100 percent for one year beginning August 2028, then 200 percent from August 2029. The stated aim is to move production to the United States, with companies that do not build domestic capacity within that window facing the full levy.

The exposure is concentrated. India's pharmaceutical companies supply close to half of all generic medicines used in the United States, making the policy a direct threat to one of that country's largest export sectors. Analysts cited by Globes warned that the tariffs could reduce supply and raise prices for American patients if domestic capacity does not expand quickly enough to replace imports.

The two-year delay is the policy's defining feature. It works as an ultimatum rather than an immediate tax, on the expectation that the threat of a 100 percent duty will draw factory investment into the United States before the tariff ever collects revenue. Whether that capital appears, or whether importers simply pass higher costs to consumers, will determine whether the measure moves production onshore or mainly raises the price of medicine.

## What this means

Generic drugmakers in India and other low-cost producers face a firm deadline. They must invest in US plants or lose access to their largest market at a 100 to 200 percent cost penalty. The channel to American consumers runs through supply and price, because generics are the low-cost foundation of the US drug system, and any gap between reshored capacity and lost imports would appear as shortages or higher prices. The delayed structure means the near-term effect is on investment decisions and the stock valuations of Indian exporters rather than on today's drug prices.

## What to watch

- Whether major Indian generic manufacturers announce US plant investments before August 2028, which would signal the tariff threat is working as intended rather than simply raising costs.
- Industry warnings about specific drug shortages, since generics already run on narrow profit margins and some producers may leave the US market rather than absorb the tariff or build domestically.